MET Register

Pediatric oncology/hematology
Solid tumors, Rare tumors
Register and supportive Studies
Recommendations on the diagnosis, treatment and aftercare of malignant endocrine tumours in children and adolescents are not part of the new MET Registry (protocol). For the entities covered by the MET registry (ACT, DTC, MTC, NET, PPGL), the physicians responsible for their treatment are provided with published national recommendations on diagnosis and treatment based on current knowledge and current analyses of the MET registry, which are not part of the registry protocol. A European recommendation is already available for the entity of ACT (Virgone, C., et al., Pediatr Blood Cancer, 2021). If required, a patient-specific counselling request can be submitted to the MET Help Desk. For this purpose, a corresponding declaration of consent must be obtained from the treating clinic for the respective patient (aged 16 and over) and/or their legal guardian. Translated with DeepL.com (free version)
Recommendations on the diagnosis, treatment and aftercare of malignant endocrine tumours in children and adolescents are not part of the new MET Registry (protocol). For the entities covered by the MET registry (ACT, DTC, MTC, NET, PPGL), the physicians responsible for their treatment are provided with published national recommendations on diagnosis and treatment based on current knowledge and current analyses of the MET registry, which are not part of the registry protocol. A European recommendation is already available for the entity of ACT (Virgone, C., et al., Pediatr Blood Cancer, 2021). If required, a patient-specific counselling request can be submitted to the MET Help Desk. For this purpose, a corresponding declaration of consent must be obtained from the treating clinic for the respective patient (aged 16 and over) and/or their legal guardian. Translated with DeepL.com (free version)